Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
In the ASCET study, 1000 patients with documented coronary heart disease will be randomized
to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75mg/d. Clinical
endpoints will be recorded for at least 2 years and related to the initial aspirin response,
assessed by the PFA-100® method, to investigate whether aspirin non-responders have higher
composite event rate than responders or whether Clopidogrel treatment in patients
non-responsive to aspirin will reduce their risk of future clinical events. The clinical
events are the composite of unstable angina, myocardial infarction, stroke or death.
Phase:
Phase 4
Details
Lead Sponsor:
Ullevaal University Hospital
Collaborators:
Ada and Hagbart Waages Humanitarian and Charity Foundation Alf and Aagot Helgesens Research Foundation. The Norwegian Council for Cardiovascular Diseases.